Trials / Terminated
TerminatedNCT03803163
A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers
A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of TransCon PEG Treprostinil Administered as a Subcutaneous Injection in Healthy Adult Male Volunteers
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Ascendis Pharma A/S · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To determine the maximum tolerated dose (MTD) and assess safety and tolerability of escalating single doses of TransCon PEG treprostinil administered as a subcutaneous injection to healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TransCon Treprostinil |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2019-01-14
- Last updated
- 2019-01-14
Source: ClinicalTrials.gov record NCT03803163. Inclusion in this directory is not an endorsement.